PharmaMar Group companies


PharmaMar is a leading oncology biopharmaceutical company dedicated to advancing cancer treatment through the discovery and development of innovative marine-derived medicines. The company’s vision is to provide new drugs from unexplored marine sources that address society’s need for new, more potent cancer therapies to improve patients’ lives. PharmaMar is the only company that has implemented a program focused on the discovery and development of drugs based on marine-derived agents.

Sylentis is a research company wholly owned by the Zeltia Group. Its objective is to discover and develop new therapies based on RNA interference (RNAi) technology, both for untreated diseases and for those with a treatment that needs to be improved.

Other useful links

SEIMC. Spanish Society of Infectious Diseases and Clinical Microbiology

SEAP. Spanish Society of Pathological Anatomy

Spanish Association of Cervical Pathology and Colposcopy

SEV. Spanish Society of Virology

SEOM. Spanish Society of Medical Oncology

AEMPS. Spanish Agency of Medicines and Health Products

Carlos III Health Institute

AECC. Spanish Association for the Fight against Cancer

ASEBIO. Spanish Association of Biocompanies

FENIN. Spanish Federation of Health Technology Companies

MedTech Europe.European Trade Association for Medical Technology Industry

WHO. World Health Organization